Latest From Biotech Now

Stretching Your Dollar: Methods and Tools for Increasing the Productivity of Clinical Trials


Recent Tufts data show clinical trials typically take nearly twice as long to complete enrollment as predicted at launch and 48% of trial sites miss enrollment targets.  Delays in trials shrink the returns from patent exclusivity and increase R&D costs.  New methods such as adaptive and batch trial designs, as well as explosive growth in digital tools, such as Apple’s ResearchKit, have transformed the trial design choices available.  These innovations, and others, provide new levers Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Senate Hearing Stresses Confidence in the Safety, Regulation of GMOs

As the debate over GMO food labeling and the use of biotechnology in agriculture has evolved, the Senate Committee on Agriculture hosted a hearing today, “Agriculture Biotechnology: A Look at Federal Regulation and Stakeholder Perspectives,” to hear perspectives from agency officials, food producers and consumer groups.  Committee members also asked witnesses their perspectives on whether or not GMO foods should require labels.  Committee members emphasized the need for science-based policies and the witness testimonies mostly Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Fireside Chat: James Noble Says Go for IPO


“Go for it,” was the parting advice James Noble, CEO and co-founder of Adaptimmune, had for pre-IPO biotech companies attending today’s BIO Investor Forum fireside chat. But, he said, be prepared for scrutiny from all sides… and mountains of paperwork. James co-founded Adaptimmune, a clinical-stage immunotherapy biopharmaceutical company, in July of 2008. At that time he was also part-time CEO of Immunocore, also a clinical-stage company engaged in T-cell receptor researches and develop. From this Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Biotech Policy Outlook at #BIF15: 21st Century Cures, IPR, TPP, and PDUFA VI

BIO Investor Forum

To even the most casual observer, 2015 has been a big year in the biotech industry, particularly in Congress and in other venues wherein public policies that affect the sector take shape. Given the importance of the policy environment in determining how successful companies in our industry can be at delivering new cures and treatments to patients – and a return to the investors who finance their activities – we decided that a close look Read More >

Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Roll Call: Patient-Centeredness, Comparative Effectiveness, and Value

In Roll Call, Tony Coelho former House Majority Whip, Chairman of the Partnership to Improve Patient Care (PIPC) and author of the Americans with Disabilities Act (ADA) discussed the need for a patient-centered approach to healthcare. Coelho says: “Policymakers talk about the “value” of treatments as if there is one value algorithm that applies to all patients equally. While that may be true in academia, in the real world value is personal. Research on treatment Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,